The pharmacovigilance (PV) market is undergoing a seismic shift. As life sciences companies race to bring innovative therapies to market, the demand for robust, efficient, and technology-driven safety systems has never been greater. According to Precedence Research, the global pharmacovigilance market—valued at USD 9.5 billion in 2024—is projected to reach USD 22.25 billion by 2034, growing at a CAGR of 8.88%. This growth is fueled by the twin forces of increased drug development activity and heightened regulatory scrutiny.
In this rapidly evolving landscape, Cloudbyz is uniquely positioned to help pharmaceutical, biotech, and medical device companies, as well as CROs, navigate the complexities of global safety monitoring while improving efficiency, compliance, and speed to action.
The largest share of pharmacovigilance activity—76% of revenue—comes from Phase IV or post-marketing surveillance. These activities are crucial to identifying long-term safety trends and rare adverse events that may not emerge during clinical trials. Traditional systems often struggle to scale or adapt quickly to the volume and complexity of post-market data, leading to delays in signal detection and risk mitigation.
Signal detection processes already account for 39.6% of PV revenues, and AI is transforming how this work is done. By analyzing structured and unstructured data sources—ranging from clinical trial databases to social media chatter—AI-driven PV platforms can detect safety signals faster and with greater accuracy.
Oncology alone represents 26.8% of PV revenues, underscoring the importance of therapeutic-specific expertise in pharmacovigilance systems. At the same time, emerging markets, particularly in Asia-Pacific (CAGR 10.9%), are creating a demand for scalable, multi-language, regionally compliant solutions.
At Cloudbyz, we believe pharmacovigilance should be intelligent, compliant, and adaptable. Our Cloudbyz Safety & Pharmacovigilance solution, built natively on the Salesforce platform, delivers an end-to-end, cloud-native system designed for the modern PV ecosystem.
Cloudbyz integrates advanced AI and automation capabilities to enhance:
Signal detection and prioritization, reducing time-to-signal and false positives.
Automated case processing, from intake to submission, freeing safety teams to focus on analysis and decision-making.
Predictive risk assessment, leveraging historical and real-time data to anticipate potential safety issues.
Regulatory compliance is non-negotiable. Cloudbyz provides:
Pre-configured templates and workflows for FDA, EMA, PMDA, MHRA, and CDSCO.
Built-in audit trails, role-based access controls, and GxP-compliant infrastructure.
Configurability to adapt to evolving regulations without costly reimplementation.
Whether supporting a global CRO with dozens of sponsors or a rapidly growing biotech:
Multi-tenant architecture supports multiple programs, sponsors, and geographies from a single instance.
Multi-language support and region-specific compliance features accelerate deployment in emerging markets.
Cloud-native delivery eliminates infrastructure bottlenecks and shortens implementation timelines.
Our solution can be tailored to high-complexity therapeutic areas like oncology, rare diseases, and immunology—addressing specific workflows, safety profile considerations, and regulatory nuances.
The pharmacovigilance market is populated by established players like Veeva Vault Safety, ArisGlobal, and Oracle Argus. Yet many legacy systems are costly, inflexible, and slow to adapt to changing needs.
Cloudbyz differentiates itself by:
Native Salesforce architecture for unmatched configurability and integration across CTMS, EDC, eTMF, and Safety—enabling a unified eClinical environment.
Faster time-to-value through low-code customization and pre-built compliance modules.
AI-first design, embedding automation and decision support into every stage of the PV workflow.
In the coming decade, pharmacovigilance will no longer be seen purely as a compliance function—it will be a strategic differentiator. Organizations that can detect and respond to safety signals faster will gain the trust of regulators, healthcare providers, and patients alike.
Cloudbyz’s vision is to enable exactly that—a pharmacovigilance function that is proactive, intelligent, and seamlessly connected to the broader clinical and commercial ecosystem.
For companies seeking to modernize their drug safety operations and prepare for the next era of pharmacovigilance, Cloudbyz offers not just software, but a platform for transformation.
Final Word:
The pharmacovigilance market is growing, but so is the complexity of ensuring drug safety. Cloudbyz stands ready—with technology, expertise, and a unified platform approach—to help organizations navigate this critical mission with speed, precision, and confidence.